- Product
- The Court rejects petitions on drug pricing negotiations
- by Kang, Shin-Kook May 3, 2024 05:53am
- The Constitutional Court of Korea (hereafter referred to as the Constitutional Court) made a decision to reject pharmaceutical company’s petition, which alleged a constitutional violation related to the drug pricing negotiations order. The Constitutional Court recently announced that the clause of a claim, including the violation of th
- Company
- Roche Korea appoints Ezat Azem as new general manager
- by Son, Hyung-Min May 3, 2024 05:52am
- Roche Korea announced that it had appointed Ezat Azem as the new general manager, effective as of May 1. The new GM first joined Roche’s Israel subsidiary in 1997, after which he served nearly 27 years in the group as a marketing division leader in Romania, Slovenia, and other countries around the world, contributing to the launch and gr
- Company
- 'Leclaza’s 5 counts of clinical results' to be showcased
- by Son, Hyung-Min May 2, 2024 05:53am
- It has been noted whether new anti-cancer candidates from the pharmaceutical and biotech industry in South Korea will be competitive on a global setting. According to industry sources on April 2nd, various Korean pharmaceutical companies, including Yuhan, HLB, and GI Innovation, will attend the 2024 American Society of Clinical Oncology
- Company
- Yuhan earns KRW253.2B through licensing-out deals in 5 yrs
- by Chon, Seung-Hyun May 2, 2024 05:52am
- Yuhan Corp has secured a solid source of revenue with technology licensing fees. Billions of won in profit have been steadily flowing in every quarter through technology licensing deals, the investing company’s development progress, and milestone payments. Yuhan Corp’s cumulative technology fee over the past 5 years amounted to KRW 253.2 billi
- Policy
- 1488 drugs approved last year…30% diabetes drugs
- by Lee, Hye-Kyung May 2, 2024 05:52am
- A total of 1488 drugs were found to be approved by the Ministry of Food and Drug Safety last year. The MFDS said on the 30th that it published the Drug Approval Report that contains the approval, certification, and report status of drugs, quasi-drugs, and medical devices in 2023. In the case of pharmaceuticals, a total of 1,488 items were
- Policy
- 32 med schools in KOR confirm their admission quota
- by Lee, Jeong-Hwan May 2, 2024 05:52am
- The 32 medical schools that were assigned increased medical admission quota from the government confirmed their final medical admission quota for the 2025 academic year. After withdrawing the initial announcement of increasing the medical school admission quota to 2,000 students, the government allowed universities to adjust their intake
- Policy
- Gov’t will announce preferential pricing measures by June
- by Lee, Jeong-Hwan May 2, 2024 05:52am
- The government plans to prepare and announce the standards for providing preferential drug prices to pharmaceutical companies that have led healthcare innovation through R&D investment, supply of essential medicines, and job creation by June at the latest. The government will also provide preferential drug pricing for drugs that use do
- Policy
- Industry fumes over government's drug price reeval plan
- by Lee, Tak-Sun Apr 30, 2024 05:50am
- The pharmaceutical industry continues to criticize the government's plan to reevaluate Korea’s drug prices based on foreign drug prices. Not only is the industry unconvinced about the purpose of the reevaluation itself, but the industry believes that the government's proposal has been designed to disadvantage the pharmaceutical industr
- Policy
- Cancellation of Forxiga approval, HK inno.N gets indication
- by Lee, Tak-Sun Apr 30, 2024 05:50am
- AstraZeneca Korea voluntarily canceled its Korean approval for ‘Forxiga (dapagliflozin propanediol hydrate), an oral diabetes treatment, valued at KRW 50 billion. As reimbursement will be canceled soon, Forxiga’s exit from the Korean market is imminent. After the approval cancellation, Forxiga indication was transferred to HK inno.N’
- Company
- Market withdrawal and indication transfer
- by Kim, Jin-Gu Apr 30, 2024 05:49am
- AstraZeneca Korea voluntarily withdrew approval for ‘Forxiga (dapagliflozin),’ an SGLT-2 inhibitor class diabetes treatment, and transferred the chronic heart failure·chronic kidney disease indication to its partnering company H.K. inno.N’s 'Dapa N.' Due to this clever co-promotion strategy between AstraZeneca Korea and HK inno.N, t
